Quality Control and Standardization of Rabeprazole Tablets Quality Control and Standardization of Rabeprazole Tablets
Iranian Journal of Pharmaceutical Sciences,
Vol. 16 No. 2 (2020),
1 Farvardin 2020
,
Page 69-86
https://doi.org/10.22037/ijps.v16.40427
Abstract
Rabeprazole sodium is a new stable pharmaceutical composition developed by us in tablet form, consisting of rabeprazole sodium as active ingredient, excipients, a separating layer and enteric coating. The manufacturing method involves pressing with preliminary wet granulation. In this work, a method was developed for the quantitative determination of rabeprazole sodium in tablets with simultaneous determination of impurities, using high-performance liquid chromatography with diode-array detection. Chromatographic conditions were established for the separation of rabeprazole and impurities on С18 sorbent, using mobile phase: 0.05% К2НР04, 0.27% КН2Р04 with pH 6.8; and acetonitrile in ratio of 70:30 (v/v), using isocratic elution mode. Furthermore, a method was developed for the spectrophotometric determination of rabeprazole sodium and the conditions of its release during dissolution test were optimized. The feasibility of the developed techniques for the analysis of enteric coated rabeprazole tablets was evaluated with the following parameters: specificity, accuracy, stability of solutions, linearity, convergence, and reproducibility. The techniques were confirmed suitable for the determination of impurities in the drug and for its quantitative analysis.
- Dissolution test
- high-performance liquid chromatography
- rabeprazole sodium
- spectrophotometry
- tablets
- quality control
How to Cite
References
[2] Kareva EN. Rabeprazole through the prism of "metabolism - efficiency". Russ. Open Med. J. (2016) 17: 1172-1176.
[3] Khannanov TSh, Anisimov AN, Chuvashova DP, Egorova SN, Lefterova MI and Khamidullin RT. Pharmaceutical composition containing rabeprazole and method for producing it. Patent RU 2554735 (27.06.2015). Available from: URL: https://patents.google.com/patent/RU2554735C1/ru
[4] Khalil MT, Usman M, Bakhsh S, Bibi H, Siddiqua and Alia R. Validated HPLC method for the determination of rabeprazole in bulk and pharmaceutical dosage form. j. biomed. pharm. Res. (2013) 2(1): 15-18.
[5] Pandey G, Mishra K. Spectrophotometric method for estimation of rabeprazole sodium in tablets. Int. Res. J. Pharm. (2013) 3(4): 193-195.
[6] Reddy RB, Goud TV, Nagamani NJ, Alagudurai A, Murugan R, Parthasarathy K, Karthikeyan V and Saravanan S. Structural identification and characterization of potential impurities of rabeprazole sodium. J. Chem. Pharm. Res. (2012) 4(1): 130-139.
[7] Raghava RTV, Kumar RS, Mrutyunjaya RI, Someswara RN. Development and validation of a stability indicating HPLC method for the estimation of rabeprazole impurities in pharmaceutical dosage forms by design of experiments. Asian J. Pharm.Clin. Res. (2013) 6(4): 43-51.
[8] Dissolution for solid dosage forms. In: State Pharmacopoeia of Russian Federation, 14th ed.Moscow (2018) 2: 2164-2182. Available from: URL:http://resource.rucml.ru/feml/pharmacopia/14_2/HTM
L/367/index.html
- Abstract Viewed: 395 times
- IJPS_Volume 16_Issue 2_Pages 69-86 Downloaded: 285 times